.RESEARCH STUDY HIGHLIGHT.06 August 2024.
A large randomized controlled trial with cisgender ladies highlights the challenges of obedience to a daily oral preexposure treatment regiment and demonstrates that twice-yearly shot of lenacapavir may preserve helpful HIV deterrence amounts over 6 months.